Withdrawal from drugs and alcohol is a common medical problem seen in most countries. The withdrawal response after discontinuation of a particular drug or alcohol can depend on how long it was used for. There is a tremendous variability in the withdrawal response. When people consume alcohol for at least 1 to 3 months or even consume large quantities for at least seven to ten days, the withdrawal response can occur within 6 to 24 hours after cessation of alcohol. The withdrawal response is relieved immediately by consuming additional alcohol.
AlcoholEthanol intoxication and withdrawal is complex. Most effects can be explained by the interaction of ethanol with neurotransmitters and neuroreceptors including gamma-aminobutyric acid (GABA), glutamate (NMDA), and opiates which result in changes in the inhibitory and excitation neurotransmitters disrupting the neurochemical balance in the brain, causing symptoms of withdrawal. Ethanol inhibits opioid binding to P-opioid receptors, and long-term use results in upregulation of opioid receptors. Opioid receptors in the nucleus accumbens and the ventral tegmental area of the brain modulate ethanol-induced dopamine release, this, in turn, produces alcohol craving and use of opioid antagonists to prevent this craving.Opioids
In opioid or benzodiazepine addiction, chronic stimulation of specific receptors for these drugs suppresses endogenous production of neurotransmitters, endorphins or GABA. Removal of the exogenous drug allows unopposed counter-regulatory effects. When the exogenous drug is removed, inadequate production of endogenous transmitters and unopposed stimulation by counter-regulatory transmitters results in withdrawal symptoms. The time it takes to restore homeostasis by synthesis of endogenous transmitters determines the time course of withdrawal.
Withdrawal from drugs and alcohol is a common medical problem. Five to ten percent of the population has alcoholism. As many as 5% of these patients may develop delirium tremens (DT) when they withdraw from chronic alcohol use. The number of people addicted to opioids, sedatives, and stimulants is not known. The mortality rate from alcohol withdrawal and DT is high if untreated. Opiate withdrawal is uncomfortable, but fatalities are rare. Withdrawal from cocaine and amphetamine results in sedation and a state resembling adrenergic blockade, death is rare. Chronic alcoholism and withdrawal are more common in men than women.
The signs and symptoms of alcohol withdrawal may range from a simple tremor to a fully blown delirium tremens characterized by autonomic hyperactivity, tachypnea, hyperthermia, and diaphoresis. About 25% of patients may develop alcohol hallucinations which are commonly auditory. Some alcoholics may develop seizures which are brief.
On exam, the alcoholic withdrawal response signs may include hyperventilation, tachycardia, tremor, hypertension, diaphoresis or hypothermia. Signs of chronic alcoholism may include spider angiomata, flushed facies, paralysis of extraocular muscles (Wernicke encephalopathy), poor dentition, skull or facial trauma (as a result of falls) and tongue lacerations (biting tongue during seizures). Other features of chronic alcoholism include ascites, hepatosplenomegaly, and melena. Thinning of hair, spider angioma, and gynecomastia are all also seen in chronic alcoholics.
Many patients with alcohol withdrawal have additional medical or traumatic conditions that may increase their associated risk of morbidity and mortality. Risk factors associated with increased mortality include cirrhosis, the presence of DTs at the time of diagnosis, the existence of underlying chronic pathology other than liver disease, and a need for endotracheal intubation.
Barbiturates and Benzodiazepines
Use of sedatives like barbiturates and benzodiazepines can also produce withdrawal responses that resemble alcohol withdrawal syndrome. Autonomic and psychomotor dysfunction often characterize the withdrawal symptoms. The symptoms tend to develop 2 to 10 days after discontinuation of the agent. Gamma Hydroxybutyrate (GHB) is now a common club drug abused at nightclubs and all-night parties. The withdrawal response is mild, resembles a sedative withdrawal syndrome with psychotic symptoms. Severe withdrawal symptoms tend to occur in chronic users and can also present with seizures and rhabdomyolysis.
Opiate withdrawal response is usually mild and not life-threatening. It usually resembles a flu-like illness characterized by yawning, sneezing, rhinorrhea, nausea, diarrhea, vomiting, and dilated pupils. Depending on the half-life of the drug, the symptoms may last for three to ten days. Also, individuals who abuse IV drugs are prone to infections like endocarditis, osteomyelitis, cellulitis, hepatitis, and septic emboli.
Opiate addicts may have signs of a cough, hemoptysis, and tachypnea due to opportunistic infections as a result of acquiring HIV and PCP. IV drug users may have scars and needle marks.
Cocaine and Amphetamines
Central nervous system (CNS) stimulants like cocaine and amphetamine can also produce a withdrawal response. Like opiates, the withdrawal response is mild and not life-threatening. Often the individual will develop marked depression, excessive sleep, hunger, dysphoria, and severe psychomotor retardation but all vital functions are well preserved. These individuals are not motivated to do anything but sleep. Recovery is usually slow, and depression can last for several weeks.
Patients in alcohol withdrawal may have numerous potentially life-threatening medical problems. Administration of intravenous glucose to patients with seizures is controversial because this is thought to precipitate acute Wernicke encephalopathy in chronic alcoholism unless thiamine is also administered. Lorazepam can be administered to control seizures. If glucose testing reveals hypoglycemia, dextrose 50% in water (D50W) 25 mL to 50 mL and Thiamine 100 mg intravenously (IV) is also indicated. Low doses of clonidine can help reverse central adrenergic discharge, relieving tachypnea, tachycardia, hypertension, tremor, and craving for alcohol. In an agitated patient, neuroleptics such as haloperidol 5 mg IV or intramuscularly (IM) may be added to sedative-hypnotic agents as an adjunctive therapy. Caution must be taken because haloperidol may decrease the seizure threshold as well as prolong the QT interval.
Patients exposed to opioids for longer than 14 days usually need to be weaned over time. Withdrawal symptoms should be assessed with the Sophia Observation Withdrawal Symptoms Scale. Weaning protocols should consider the length of opioid exposure and total daily opioid dose. Opioid withdrawal is treated with a long-acting opioid agonist, such as methadone or buprenorphine. Clonidine may also decrease the severity of symptoms. Long-acting benzodiazepines may be used to control insomnia and muscle cramps.Sedative-Hypnotic
Sedative-hypnotic withdrawal is treated with substituting drugs that have a long duration of action, benzodiazepine or phenobarbital for a few days followed by a decreasing dose over 2 to 3 weeks.
GHB withdrawal can initially be treated with high doses of benzodiazepines, refractory cases have responded to pentobarbital, chloral hydrate, and baclofen.
Stimulant-withdrawal syndrome is treated with observation.
Patients with DTs or other severe withdrawal symptoms may require admission to the intensive care unit due to the risk of mortality.
Patients with chronic alcoholism or intravenous drug use should be evaluated for inpatient and outpatient treatment programs. Treatment programs are only successful if the patient is motivated. Often individuals addicted to opiates will be placed on methadone or buprenorphine.
Psychiatric evaluation is strongly recommended to rule out mental health concerns such as suicidal ideation, major depression, and poly-substance abuse.
The management of patients undergoing withdrawal symptoms is interdisciplinary. The severity of the withdrawal symptoms depends on the type of agent and duration of use. Some patients with mild withdrawal symptoms can be managed as outpatients but those with alcohol withdrawal may require admission. Besides the psychiatrist, other healthcare professionals that should be involved in the management of these patients include the internist, neurologist, pain specialist, intensivist, mental health nurse, pharmacist, and sometimes a cardiologist. The nurse should assist in patient monitoring and education. The pharmacist should evaluate for drug-drug interactions and assist in selection and dosing of drugs used to control withdrawal symptoms. The outcomes depend on the agent ingested. For most patients relapses and remissions are very common following addiction to drugs and alcohol. (Level V)
|||Gulati P,Chavan BS,Sidana A, Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. Indian journal of psychiatry. 2019 Jan-Feb; [PubMed PMID: 30745655]|
|||Mangat AK,Schmölzer GM,Kraft WK, Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). Seminars in fetal [PubMed PMID: 30745219]|
|||Cooney G,Heydtmann M,Smith ID, Baclofen and the Alcohol Withdrawal Syndrome-A Short Review. Frontiers in psychiatry. 2018; [PubMed PMID: 30723432]|
|||Tang B,Wang XT,Chen WJ,Zhu SH,Chao YG,Zhu B,He W,Wang B,Cao FF,Liu YJ,Fan XJ,Yang H,Xu QH,Zhang H,Gong RC,Chai WZ,Zhang HM,Shi GZ,Li LH,Huang QB,Zhang LN,Yin MG,Shang XL,Wang XM,Tian F,Liu LX,Zhu R,Wu J,Wu YQ,Li CL,Zong Y,Hu JT,Liu J,Zhai Q,Deng LJ,Deng YY,Liu DW, [Experts consensus on the management of delirium in critically ill patients]. Zhonghua nei ke za zhi. 2019 Feb 1; [PubMed PMID: 30704197]|
|||Ibarra F Jr, Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal. The American journal of emergency medicine. 2019 Jan 30; [PubMed PMID: 30744913]|
|||Glann JK,Carman M,Thompson J,Olson D,Nuttall C,Fleming H,Reese C, Alcohol Withdrawal Syndrome: Improving Recognition and Treatment in the Emergency Department. Advanced emergency nursing journal. 2019 Jan/Mar; [PubMed PMID: 30702536]|
|||Duceppe MA,Perreault MM,Frenette AJ,Burry LD,Rico P,Lavoie A,Gélinas C,Mehta S,Dagenais M,Williamson DR, Frequency, risk factors and symptomatology of iatrogenic withdrawal from opioids and benzodiazepines in critically Ill neonates, children and adults: A systematic review of clinical studies. Journal of clinical pharmacy and therapeutics. 2018 Dec 19; [PubMed PMID: 30569508]|
|||Bichaff P,Setani KT,Motta EHG,Delgado AF,Carvalho WB,Luglio M, Opioid tapering and weaning protocols in pediatric critical care units: a systematic review. Revista da Associacao Medica Brasileira (1992). 2018 Oct; [PubMed PMID: 30517238]|
|||Mo Y,Thomas MC,Laskey CS,Shcherbakova N,Bankert ML,Halloran RH, Current Practice Patterns in the Management Of Alcohol Withdrawal Syndrome. P [PubMed PMID: 29491698]|
|||Campbell EJ,Lawrence AJ,Perry CJ, New steps for treating alcohol use disorder. Psychopharmacology. 2018 Jun; [PubMed PMID: 29574507]|
|||Lumish R,Goga JK,Brandt NJ, Optimizing Pain Management Through Opioid Deprescribing. Journal of gerontological nursing. 2018 Jan 1; [PubMed PMID: 29355883]|